Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review

References

• Guan W, Lan W, Zhang J, et al. COVID-19: antiviral agents, antibody development and traditional Chinese medicine. Virol Sin. 2020;35(6):685–698. doi:10.1007/s12250-020-00297-0
   PubMed Web of Science ®Google Scholar
• Abuin P, Anderson A, Ferramosca A, Hernandez-Vargas EA, Gonzalez AH. Dynamical characterization of antiviral effects in COVID-19. Annu Rev Control. 2021. doi:10.1016/j.arcontrol.2021.05.001
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21(2):167–179. doi:10.1007/s10238-020-00671-y
   PubMed Web of Science ®Google Scholar
• Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: progress in diagnostics, therapy and vaccination. Theranostics. 2020;10(17):7821–7835. doi:10.7150/thno.47987
   PubMed Web of Science ®Google Scholar
• Paules CI, Marston HD, Fauci AS. Coronavirus infections—more than just the common cold. J Am Med Assoc. 2020;323(8):707–708. doi:10.1001/jama.2020.0757
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus disease 2019 (COVID-19): a review. J Am Med Assoc. 2020;323(18):1824–1836.
   PubMed Web of Science ®Google Scholar
• Torneri A, Libin P, Vanderlocht J, Vandamme AM, Neyts J, Hens N. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. BMC Med. 2020;18(1):1–9.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Borbone N, Piccialli G, Roviello GN, Oliviero G. Nucleoside analogs and nucleoside precursors as drugs in the fight against SARS-CoV-2 and other coronaviruses. Molecules. 2021;26(4):1–17. doi:10.3390/molecules26040986
   Web of Science ®Google Scholar
• Munir MA, Kuganda H, Basry A. The efficacy and safety of antivirus drugs for COVID-19: a systematic review. Syst Rev Pharm. 2020;11(7):162–166.
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:1–8.
   Google Scholar
• Higgins JPT, Savović J, Matthew J; Page JAS on behalf of the RDG. Risk of bias tools - Current version of RoB 2 [Internet]; 2019. Available from: https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2. Accessed November 9, 2021.
   Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827–1837. doi:10.1056/NEJMoa2015301
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. J Am Med Assoc. 2020;324(11):1048–1057. doi:10.1001/jama.2020.16349
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 — interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807. doi:10.1056/NEJMoa2031994
   PubMed Web of Science ®Google Scholar
• Reis G, Moreira Silva EA, Medeiros Silva DC, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. 2021;4(4):1–14. doi:10.1001/jamanetworkopen.2021.6468
   Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Solaymani-dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;95:107522. doi:10.1016/j.intimp.2021.107522
   PubMed Web of Science ®Google Scholar
• Khamis F, Al Naabi H, Al Lawati A, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021;102:538–543. doi:10.1016/j.ijid.2020.11.008
   PubMed Web of Science ®Google Scholar
• Lou Y, Liu L, Yao H, et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci. 2021;157:105631.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: a multicenter trial in a small sample size. Biomed Pharmacother. 2021;133:110825. doi:10.1016/j.biopha.2020.110825
   PubMed Web of Science ®Google Scholar
• Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021;166(3):949–954. doi:10.1007/s00705-021-04956-9
   PubMed Web of Science ®Google Scholar
• Dabbous HM, El-Sayed MH, El Assal G, et al. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: a randomised controlled trial. Sci Rep. 2021;11(1):1–7. doi:10.1038/s41598-021-85227-0
   PubMed Web of Science ®Google Scholar
• Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, Phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71. doi:10.1016/j.ijid.2020.11.142
   PubMed Web of Science ®Google Scholar
• Mercatelli D, Holding AN, Giorgi FM. Web tools to fight pandemics: the COVID-19 experience. Brief Bioinform. 2021;22(2):690–700. doi:10.1093/bib/bbaa261
   PubMed Web of Science ®Google Scholar
• Arthi V, Parman J. Disease, downturns, and wellbeing: economic history and the long-run impacts of COVID-19. Explor Econ Hist. 2021;79:101381. doi:10.1016/j.eeh.2020.101381
   PubMed Web of Science ®Google Scholar
• Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501–508. doi:10.1016/j.ijid.2020.10.069
   PubMed Web of Science ®Google Scholar
• Piscoya A, Ng-Sueng LF, Del Riego AP, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. PLoS One. 2020;15(12):1–19. doi:10.1371/journal.pone.0243705
   Web of Science ®Google Scholar
• Gholamhoseini MT, Yazdi-Feyzabadi V, Goudarzi R, Mehrolhassani MH. Safety and efficacy of remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24(13):237–245. doi:10.18433/jpps31870
   PubMedGoogle Scholar
• Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021;11(6):1–9. doi:10.1136/bmjopen-2020-048416
   Web of Science ®Google Scholar
• Davies M, Osborne V, Lane S, et al. Remdesivir in treatment of COVID-19: a systematic benefit–risk assessment. Drug Saf. 2020;43(7):645–656. doi:10.1007/s40264-020-00952-1
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CH, Wang CY, Chen KH, Wang YH, Hsueh PR. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021;76(8):1962–1968. doi:10.1093/jac/dkab093
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021;57(4):2100048. doi:10.1183/13993003.00048-2021
   PubMed Web of Science ®Google Scholar
• Taha HR, Keewan N, Slati F, Al-Sawalha NA. Remdesivir: a closer look at its effect in COVID-19 pandemic. Pharmacology. 2021;106(9–10):462–468. doi:10.1159/000518440
   PubMed Web of Science ®Google Scholar
• Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347.
   PubMed Web of Science ®Google Scholar
• Horby PW, Mafham M, Bell JL, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352.
   PubMed Web of Science ®Google Scholar
• Joseph BA, Dibas M, Evanson KW, et al. Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: a systematic review. Expert Rev Anti Infect Ther. 2021;19(6):679–687. doi:10.1080/14787210.2021.1848545
   PubMed Web of Science ®Google Scholar
• Li Y, Xie Z, Lin W, et al. Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. Med. 2020;1(1):105–113. doi:10.1016/j.medj.2020.04.001
   PubMed Web of Science ®Google Scholar
• Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical−therapeutic staging proposal. J Hear Lung Transplant. 2020;39(5):405–407. doi:10.1016/j.healun.2020.03.012
   PubMed Web of Science ®Google Scholar
• Lepage M-A, Rozza N, Kremer R, Grunbaum A. Safety and efficacy concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series. Clin Toxicol. 2021:1–4. doi:10.1080/15563650.2020.1842882
   Web of Science ®Google Scholar
• Lu J-M, Zhou A-F, Zhang XB, et al. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis. Eur Rev Med Pharmacol Sci. 2021;25:549–555.
   PubMed Web of Science ®Google Scholar
• Grimaldi D, Aissaoui N, Blonz G, et al. Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study. Ann Intensive Care. 2020;10(131):1–11. doi:10.1186/s13613-020-00751-y
   PubMed Web of Science ®Google Scholar
• Martínez VG, Salas AA, Ballestín SS. Antiviral therapeutic approaches for SARS-CoV-2 infection: a systematic review. Pharmaceuticals. 2021;14(736):1–26.
   Google Scholar
• Özlüşen B, Kozan Ş, Akcan RE, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;1–9. doi:10.1007/s10096-021-04307-1
   Web of Science ®Google Scholar
• Sada M, Saraya T, Ishii H, et al. Detailed molecular interactions of favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus polymerases in silico. Microorganisms. 2020;8(10):1–9. doi:10.3390/microorganisms8101610
   Web of Science ®Google Scholar
• Seneviratne SL, Abeysuriya V, de Mel S, de Zoysa I, Niloofa R. Favipiravir in COVID-19. Int J Progr Sci Technol. 2020;19(2):143–145.
   Google Scholar
• Łagocka R, Dziedziejko V, Kłos P, Pawlik A. Favipiravir in therapy of viral infections. J Clin Med. 2021;10(273):1–16. doi:10.3390/jcm10020273
   Web of Science ®Google Scholar
• Ghasemnejad-Berenji M, Pashapour S. Favipiravir and COVID-19: a simplified summary. Drug Res. 2021;71(3):166–170. doi:10.1055/a-1296-7935
   PubMed Web of Science ®Google Scholar
• Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):1–13. doi:10.1186/s12879-021-06164-x
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192–1198. doi:10.1016/j.eng.2020.03.007
   Web of Science ®Google Scholar
• Tejaswi P, Devashish K, Prasad RR. Pharmacological effects of favipiravir on coronavirus: an update. Biomed Pharmacol J. 2021;14(2):1087–1095. doi:10.13005/bpj/2212
   Google Scholar
• Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45–51. doi:10.1016/S2055-6640(20)30016-9
   PubMed Web of Science ®Google Scholar
• Ozudogru O, Yerlikaya E, Alayunt NO, Cambay Z. Evaluation of favipiravir treatment before intensive care in COVID-19 patients. J Teknol Lab. 2021;1:22–30.
   Google Scholar
• Instiaty DIGAAPS, Marzuki JE, Angelia F, et al. Antiviral treatment of COVID-19: a clinical pharmacology narrative review. Med J Indones. 2020;29(3):332–345. doi:10.13181/mji.rev.204652
   Web of Science ®Google Scholar
• World Health Organization. Therapeutics and COVID-19: LIVING GUIDELINE. World Health Organization; 2021:1–71
   Google Scholar
• Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312–320. doi:10.1136/postgradmedj-2020-138577
   PubMed Web of Science ®Google Scholar
• Costanzo M, De Giglio MAR, Roviello GN. Anti-Coronavirus vaccines: past investigations on SARS-CoV-1 and MERS-CoV, the approved vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under development against SARS-CoV-2 infection. Curr Med Chem. 2021;28:1–15. doi:10.2174/0929867328666210521164809
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ. 2021; 372 :n71 doi:10.1136/bmj.n71.
   Google Scholar